Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes
Siddhartha Dutta,Rima B Shah,Shubha Singhal,Sudeshna Banerjee Dutta,Sumit Bansal,Susmita Sinha,Mainul Haque
DOI: https://doi.org/10.2147/DDDT.S409373
2023-06-26
Abstract:Siddhartha Dutta, 1 Rima B Shah, 1 Shubha Singhal, 1 Sudeshna Banerjee Dutta, 2 Sumit Bansal, 3 Susmita Sinha, 4 Mainul Haque 5 1 Department of Pharmacology, All India Institute of Medical Sciences, Rajkot, Gujarat, India; 2 Department of Medical Surgical Nursing, Shri Anand Institute of Nursing, Rajkot, Gujarat, 360005, India; 3 Department of Anaesthesiology, All India Institute of Medical Sciences, Rajkot, Gujarat, India; 4 Department of Physiology, Khulna City Medical College and Hospital, Khulna, Bangladesh; 5 Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kuala Lumpur, 57000, Malaysia Correspondence: Shubha Singhal, Department of Pharmacology, All India Institute of Medical Sciences-Rajkot, Ayush Block, Khanderi, Para Pipaliya, Rajkot, Gujarat, India, Tel +91 9560372056, Email Mainul Haque, Unit of Pharmacology, Faculty of Medicine and Defence Health Sciences, Universiti Pertahanan Nasional Malaysia, National Defence University of Malaysia- Kem, Perdana, Sungai Besi, Kuala Lumpur, 57000, Malaysia, Tel +60 109265543, Email Metformin has been designated as one of the most crucial first-line therapeutic agents in the management of type 2 diabetes mellitus. Primarily being an antihyperglycemic agent, metformin also has a plethora of pleiotropic effects on various systems and processes. It acts majorly by activating AMPK (Adenosine Monophosphate-Activated Protein Kinase) in the cells and reducing glucose output from the liver. It also decreases advanced glycation end products and reactive oxygen species production in the endothelium apart from regulating the glucose and lipid metabolism in the cardiomyocytes, hence minimizing the cardiovascular risks. Its anticancer, antiproliferative and apoptosis-inducing effects on malignant cells might prove instrumental in the malignancy of organs like the breast, kidney, brain, ovary, lung, and endometrium. Preclinical studies have also shown some evidence of metformin's neuroprotective role in Parkinson's disease, Alzheimer's disease, multiple sclerosis and Huntington's disease. Metformin exerts its pleiotropic effects through varied pathways of intracellular signalling and exact mechanism in the majority of them remains yet to be clearly defined. This article has extensively reviewed the therapeutic benefits of metformin and the details of its mechanism for a molecule of boon in various conditions like diabetes, prediabetes, obesity, polycystic ovarian disease, metabolic derangement in HIV, various cancers and aging. Keywords: metformin, diabetes, pleotropic effect, cancer, cardiovascular, neuroprotection, Prediabetes Metformin, as a drug, was suggested as an initial treatment for type 2 diabetes. Metformin has been used as a first-line therapy in diabetes but current guidelines suggest its use in people with a BMI between 25 and 59 kg/m 2 , higher fasting glucose (>110 mg/dL), higher A1C >6.0%, and patients with a propensity to cause gestational diabetes. 1 Currently, as per the evidence, an SGLT2 ("sodium-glucose cotransporter 2") inhibitor and/or GLP-1("glucagon-like peptide 1") receptor agonist with proven CV (cardiovascular) benefit should be used in people with type 2 diabetes with established ASCVD ("atherosclerotic cardiovascular disease") or indicators of high CV risk, established renal disease, or heart failure. 1 Metformin traces its origins to the traditional medicinal plant Galega officinalis, which was used to treat diabetes symptoms in Europe in the 18th century. It was rich in guanidine; later, many mono-guanidines (galegine) and diguanidines (synthalin) derivatives were developed. 2 The toxicity profile of these medicines prevented them from achieving widespread recognition as antidiabetic medications, even though they considerably lowered the blood glucose level in animals. 3 The three important members of the biguanide family were phenformin, buphormin, and metformin. 3,4 In the 1950s, all three biguanides were researched in humans and approved for diabetic treatment in Europe. 3,5 Due to the risk of lactic acidosis, phenformin and buphormin were removed from the market nearly 20 years after their introduction. Metformin users had a substantially reduced incidence of lactic acidosis. It occurred only in patients with compromised renal function, which itself is a contraindication for metformin use. Metformin was authorized by United States FDA (Food and Drug Administration) to treat diabetes in 1994, and it became commercially available in the following year. 3 In 1998, the UKPDS (UK Prospective Diabetes Study) found that long-term metformin -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal